Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Sees Significant Decrease in Short Interest

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the recipient of a large drop in short interest in September. As of September 30th, there was short interest totaling 1,012 shares, a drop of 80.8% from the September 15th total of 5,259 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily volume of 31,252 shares, the days-to-cover ratio is presently 0.0 days.

Cardio Diagnostics Stock Down 4.8%

CDIO stock opened at $1.78 on Tuesday. Cardio Diagnostics has a 52-week low of $0.97 and a 52-week high of $7.91. The stock’s fifty day simple moving average is $1.93 and its 200-day simple moving average is $1.88. The stock has a market capitalization of $5.27 million, a price-to-earnings ratio of -0.61 and a beta of 2.29.

Cardio Diagnostics (NASDAQ:CDIO) last released its earnings results on Friday, August 7th. The company reported ($0.51) EPS for the quarter. Cardio Diagnostics had a negative net margin of 43,133.33% and a negative return on equity of 82.28%. The business had revenue of $0.01 million during the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cardio Diagnostics in a research report on Tuesday, September 8th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cardio Diagnostics stock. Renaissance Technologies LLC bought a new position in Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 15,348 shares of the company’s stock, valued at approximately $30,000. Renaissance Technologies LLC owned about 0.52% of Cardio Diagnostics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 8.06% of the company’s stock.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc is a biotechnology company focused on developing precision medicine solutions for the prevention, detection and management of cardiovascular disease. The company combines genetic, epigenetic and clinical data with artificial intelligence to create blood-based tools designed to help identify an individual’s risk of coronary heart disease and support personalized care.

Its product portfolio has included Epi+Gen CHD, a blood-based test intended to assess a person’s susceptibility to coronary heart disease and provide information that may support preventive interventions.